SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery
SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development
SOHM, Inc., Moving and Expanding Commercialization Capabilities with its New Vista, CA Facility
SOHM Achieves Breakthrough with ABBIE Gene Editing Platform, Advancing Strategic Partnership and Licensing Opportunities
SOHM, Inc. Launches New User-Friendly Website to Enhance Customer, Investor Experience and Engagement
SOHM, Inc. Appoints Ravi Kapoor as an Independent Director
SOHM, Inc. Sets Strategic Goals to Enter Biotechnology-Driven Cosmeceuticals Market
SOHM Inc. Welcomes Dr. Larissa Karnaoukhova as New Vice President of Operations
SOHM Inc. Welcomes Dr. Lucia Piccotti to Offer Expert Guidance on Cosmeceutical and Personal Health Product Research and Development
SOHM, Inc., Unveils Genetically Engineered Ovarian Cancer Cell Line Using ABBIE(TM) Platform to Accelerate GYS1 Drug Discovery
Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization
SOHM Inc. Awarded European Patent for Innovative ABBIE Genome Editing Technology
SOHM, Inc. Announces Patent Allowance/Approval in South Korea
SOHM, Inc. Shares an Exciting Expansion and Upcoming Presentation on ABBIE
SOHM, Inc. Launches New AI Team to Advance ABBIE System and Genome Editing Innovations
SOHM, Inc. Shares Groundbreaking Findings in ABBIE Technology
SOHM, Inc. Announce Dr. Wei Zhu Onboard as Senior Marketing and Sales Consultant
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (特許庁, Tokkyochō, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes
SOHM, Inc. Continues to Build its IP Portfolio in the Gene Editing and Cell Engineering Space
SOHM, Inc. has Received ABBIE Technology Kits' Pre-Launch Pre-Orders
SOHM, Inc., Announce Dr. Tetsuya Kawamura Ph. D. Joined as a Cell Engineer and Biochemist
SOHM, Inc. has signed the Manufacturing and Supply of Skincare Topical Products with New Export Customers
SOHM, Inc., Announce a New Collaboration and Joins Forces with Stanford University
SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-cell immunotherapy from a Healthy Human Donor
SOHM, Inc., Targets Revolutionary New ABBIE Genome Editing Kits for Q3, 2024
SOHM, Inc. and Coastar Therapeutics Sign MoU and Announce Collaboration to Revolutionize Genome Editing Using Red Blood Cell Membrane Derived Carriers
SOHM Files Provisional Patent on ABBIE's ‘Smart Gene-Editing' That Uses Latest Enzymes and Guide RNA to Resolve Off-Target Gene-Editing Limitations
SOHM Announces Business Outlook for 2024
SOHM Announces New CDMO GMP Manufacturing Facility in Carlsbad, California
SOHM OTC Self-care Launches Suite of 13 New SOHM Nutrients' Brand Chewables
SOHM Collaborates with University of Arizona Center for Innovation to Advance ABBIE, a Groundbreaking Non-Viral Gene-Editing Technology
SOHM Announces Its Acquisition of ABBIE, a World-Class Gene-Editing Platform Which Can Deliver Genetic Payloads Using Non-Viral Vectors
SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical Advisor
SOHM, Inc. Announce the Appointment of Dr. David Aguilar, Ph.D. as a Chief Operating Officer with the Company with Immediate Effect
SOHM Inc. Signs LOI to Acquire Stem Cell Disruptive Technology and Patents
SOHM Inc. Announces the Closure of Finances-Funding for its Various Projects